, Volume 41, Issue 1, pp 225–229 | Cite as

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

  • Gilda Tonziello
  • Marintonietta Pisaturo
  • Antonello Sica
  • Maria Giovanna Ferrara
  • Caterina Sagnelli
  • Giuseppe Pasquale
  • Evangelista Sagnelli
  • Salvatore Guastafierro
  • Nicola Coppola
Case Report


A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months.


Occult HBV infection Rituximab Lamivudine prophylaxis Immunosuppressive diseases Onco-hematological diseases 


  1. 1.
    Yeo W, Johnoson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116:115–21.PubMedGoogle Scholar
  5. 5.
    Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.PubMedCrossRefGoogle Scholar
  10. 10.
    Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian workshop. Dig Liver Dis. 2011;43:259–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Marignani M, Marzano A. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen–negative/antibody to hepatitis B core antigen–positive patients receiving chemotherapy for onco-hematologic malignancies. J Clin Oncol. 2010;29:e210.CrossRefGoogle Scholar
  12. 12.
    Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. 2010;28:5097–100.PubMedCrossRefGoogle Scholar
  13. 13.
    Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin’s lymphoma. The International non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  14. 14.
    Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Coppola N, Masiello A, Tonziello G, Pisapia R, Pisaturo M, Sagnelli C, et al. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat. 2010;17:493–500.PubMedGoogle Scholar
  16. 16.
    Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2009;38:58–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.PubMedCrossRefGoogle Scholar
  22. 22.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRefGoogle Scholar
  23. 23.
    Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: detection and significance. Dig Dis. 2010;28:116–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Ceccarelli L, Salpini R, Sarmati L, Svicher V, Bertoli A, Sordillo P, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65(2):180–3.Google Scholar
  25. 25.
    Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007;85:16–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol. 2008;83:673–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Gilda Tonziello
    • 1
  • Marintonietta Pisaturo
    • 1
  • Antonello Sica
    • 2
  • Maria Giovanna Ferrara
    • 2
  • Caterina Sagnelli
    • 3
  • Giuseppe Pasquale
    • 1
  • Evangelista Sagnelli
    • 1
  • Salvatore Guastafierro
    • 2
  • Nicola Coppola
    • 1
  1. 1.Department of Public Medicine, Section of Infectious DiseasesSecond University of NaplesNaplesItaly
  2. 2.Haematology UnitSecond University of NaplesNaplesItaly
  3. 3.Department of Clinical and Experimental Medicine and Surgery “F Magrassi e A Lanzara”Second University of NaplesNaplesItaly

Personalised recommendations